๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 18 Beijing 15 Changsha 10 Hangzhou 8
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai18 Guangzhou18 Beijing15 Changsha10 Hangzhou8
All 39 locations
Target enrolment
to

Trials with a site in Hangzhou

8 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study
NCT07670013NSCLC
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
43
Hangzhou
2026-04-01
Recruiting
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer๏ผˆNSCLC๏ผ‰
NCT07388771NSCLC, Neoadjuvant Therapy
Qian Chu
Observational
500
Wuhan, Hangzhou
2025-12-01
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
NCT06534762NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
Zhejiang Provincial People's Hospital
Phase 2
260
Hangzhou
2024-07-15
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
NCT05882513NSCLC, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2023-05-16
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

3 of the 8 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 8 studies
PhaseStudiesRecruitingShare
Phase 24250%
Observational2125%
Phase 42025%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
Pfizer20
Second Affiliated Hospital, Zhejiang University, School of Medicine21
Hoffmann-La Roche10
Qian Chu11
Yang Fan, MD10
Zhejiang Provincial People's Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.